Free tools, free alerts. Create a free account to get sector-matched alerts and save your searches.
Create free account →
NAFDAC has intensified its regulatory oversight, issuing public alerts on counterfeit drugs, blacklisting a non-compliant manufacturer, and providing guidance on medical device reporting. These actions signal a stricter enforcement environment, requiring businesses in the pharmaceutical and medical device sectors to enhance their compliance and vigilance.
Pharmaceuticals
Medical Devices
Food and Beverages
Export/Import
Healthcare
NAFDAC joins the Federal Ministry of Health and Social Welfare, nutrition partners, and the global community in celebrating World Breastfeeding Week 2026
NAFDAC
NAFDAC celebrates World Breastfeeding Week, promoting breastfeeding as a public health priority.
May lead to increased scrutiny of breast milk substitutes and marketing practices; SMBs in baby food/nutrition should ensure compliance with marketing restrictions.
Handling Manufacturer Investigation Reports for Medical Devices and IVDs
NAFDAC
NAFDAC provides guidance on handling Manufacturer Investigation Reports for medical devices and IVDs to ensure safety and quality.
Medical device and IVD companies must establish robust procedures for complaint handling and reporting to NAFDAC.
Blacklisting of Onifam Laboratories Ltd
NAFDAC
NAFDAC blacklists Onifam Laboratories Ltd for regulatory misrepresentation and improper use of approvals, barring them from pharmaceutical business activities.
SMBs in pharma must ensure transparency and integrity in regulatory interactions to avoid severe penalties including blacklisting.
Public Alert No. 037/2026 – Alert on Suspected Counterfeit Pulmicort® (Budesonide) Inhalation Suspension
NAFDAC
NAFDAC alerts the public on suspected counterfeit Pulmicort® (Budesonide) in the market, urging vigilance.
Pharmacies and distributors must verify product authenticity and report suspicious items to NAFDAC.
Public Alert No. 036/2026 – Alert on Suspected Counterfeit Products Mimicking Forxiga® (Dapagliflozin)
NAFDAC
NAFDAC alerts on suspected counterfeit Forxiga® (Dapagliflozin) products, emphasizing the need for supply chain integrity.
Importers and retailers of pharmaceuticals must enhance due diligence and traceability to avoid counterfeit distribution.
SON rides on e-platform to facilitate international trade - Business News Nigeria
Other
SON uses an electronic platform to streamline international trade processes.
SMBs involved in import/export should leverage SON's e-platform for faster and more transparent trade facilitation.
How to Register Your Fish Farm with NEPC Nigeria: A Complete Export Guide - within nigeria
Other
Guide on registering fish farms with NEPC for export purposes.
Fish farmers and exporters should register with NEPC to access export incentives and international markets.
Increased enforcement against counterfeit pharmaceuticals
Stricter compliance requirements for medical device reporting
Need for enhanced supply chain integrity and product authentication
Opportunities for digital trade facilitation via SON e-platform
Export opportunities in agriculture (fish farming) with NEPC registration
1
Verify product authenticity and report suspected counterfeits to NAFDAC
2
Implement robust procedures for handling manufacturer investigation reports
3
Ensure transparency and integrity in all regulatory submissions to NAFDAC
4
Leverage SON's e-platform for trade facilitation
5
Register with NEPC for agricultural export businesses